問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of General Internal Medicine

National Taiwan University Cancer Center

Division of General Internal Medicine

更新時間：2023-09-19

蔡子修
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

177Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡子修

List

266Cases

2021-11-16 - 2024-02-06

Phase I/II

A Phase 1/2 Study of NM21-1480 (Anti-PDL-1/Anti-4-1BB/Anti-HSA Tri-Specific Antibody) in Adult Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    NM21-1480

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

2020-03-01 - 2022-12-30

Phase I

A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of mRNA-5671/V941 as a Monotherapy and in Combination With Pembrolizumab in Participants With KRAS Mutant Advanced or Metastatic Non-Small Cell Lung Cancer, Colorectal Cancer or Pancreatic Adenocarcinoma

  • Condition/Disease

    Advanced/Metastatic solid tumors

  • Test Drug

    V941 (mRNA-5671)/ Pembrolizumab

Participate Sites
3Sites

Recruiting3Sites

2013-08-01 - 2015-12-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2018-05-01 - 2023-09-30

Phase III

A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)

  • Condition/Disease

    TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer

  • Test Drug

    Keytruda injection

Participate Sites
15Sites

Recruiting1Sites

Terminated13Sites

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2017-10-01 - 2023-05-31

Phase III

A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)

  • Condition/Disease

    Stage IV, Metastatic Non-small Cell Lung Cancer

  • Test Drug

    Keytruda

Participate Sites
8Sites

Terminated7Sites

夏德椿
China Medical University Hospital-Taipei

未分科

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-10-15 - 2021-06-11

Phase II

A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer

  • Condition/Disease

    Metastatic Non-Small Cell Lung Cancer

  • Test Drug

    Keytruda / Epacadostat

Participate Sites
6Sites

Terminated5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-08-07 - 2021-12-31

Phase III

A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)

  • Condition/Disease

    Extensive Stage Small Cell Lung Cancer

  • Test Drug

    Keytruda

Participate Sites
8Sites

Terminated7Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2017-03-14 - 2020-11-01

Phase III

A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer

  • Condition/Disease

    ALK-positive advanced lung cancer

  • Test Drug

    Brigatinib (AP26113)

Participate Sites
6Sites

Recruiting5Sites

夏德椿
China Medical University Hospital-Taipei

未分科

陳育民
Taipei Veterans General Hospital

Division of Thoracic Medicine

2019-06-01 - 2021-09-28

Phase II

A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer

  • Condition/Disease

    Non-small Cell Lung Cancer

  • Test Drug

    M7824

Participate Sites
5Sites

Recruiting5Sites

2020-06-01 - 2022-02-09

Phase III

A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

  • Condition/Disease

    Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C

  • Test Drug

    AMG 510

Participate Sites
4Sites

Recruiting4Sites

1 22 23 24 25 26 27
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB